BIG 2 months ahead, page-8

Chrisnj - there is already approval for EU market. My bet is upfront payments for those endorsed jurisdictions. Whether it is a lump sum remittance or several smaller ones will depend on agreements signed

In regards to USA market - as you say there may be a several month wait. Anyway having been in the stock for some years now - a few more months should be mere chicken feed to you

An interesting point was brought up by Jackie at least a couple of times with Ticky interview. She talked about cost of capital and the relationship with shorting.

As the shorters had continued to push share price down, everytime Starpharma needed to do a capital raising, it meant more dilution occurred as script price was at lower levels.

Which brings me to the next point. Another capital raising will happen. It will not be this quarter. There will still be at least 26 million in the bank. I say "at least" because we could receive income from several sources

*monetizing Dep Docetaxel - estimates have a value of US$300 million on favorable results

*further agreements formalized with the work being conducted on antibody drug conjugates by Starpharma and unknown two big pharmas

Just a couple of examples that come to mind. There are many others


So when for the raising - I would say one or two quarters later (September/December). By then, those important announcements which will, from my perspective drive share price to an acceptable level ($1.50-$2.50). The cost of capital will be very mimimalistic.

Jackie continues to talk about optionality for Starpharma's dendrimer technology. We have only touched the surface.........